These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 31020807

  • 1. Association of OSR-1 With Vascular Dysfunction and Hypertension in Polycystic Kidney Disease.
    Kocyigit I, Taheri S, Eroglu E, Zararsiz G, Sener EF, Uzun I, Imamoglu H, Mehmetbeyoglu E, Unal A, Korkmaz K, Sipahioglu MH, Oymak O, Tokgoz B.
    Ther Apher Dial; 2020 Feb; 24(1):64-71. PubMed ID: 31020807
    [Abstract] [Full Text] [Related]

  • 2. Systemic Succinate, Hypoxia-Inducible Factor-1 Alpha, and IL-1β Gene Expression in Autosomal Dominant Polycystic Kidney Disease with and without Hypertension.
    Kocyigit I, Taheri S, Eroglu E, Sener EF, Zararsız G, Uzun I, Tufan E, Mehmetbeyoglu E, Korkmaz Bayramov K, Sipahioglu MH, Ozkul Y, Tokgoz B, Oymak O, Axelsson J.
    Cardiorenal Med; 2019 Feb; 9(6):370-381. PubMed ID: 31319406
    [Abstract] [Full Text] [Related]

  • 3. The association of endothelin-1 levels with renal survival in polycystic kidney disease patients.
    Kocyigit I, Eroglu E, Kaynar AS, Kocer D, Kargi S, Zararsiz G, Bayramov R, Imamoglu H, Sipahioglu MH, Tokgoz B, Dundar M, Oymak O.
    J Nephrol; 2019 Feb; 32(1):83-91. PubMed ID: 30022320
    [Abstract] [Full Text] [Related]

  • 4. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M.
    Clin J Am Soc Nephrol; 2018 Oct 08; 13(10):1493-1501. PubMed ID: 30228110
    [Abstract] [Full Text] [Related]

  • 5. Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease.
    Kocyigit I, Eroglu E, Orscelik O, Unal A, Gungor O, Ozturk F, Karakukcu C, Imamoglu H, Sipahioglu MH, Tokgoz B, Oymak O.
    J Nephrol; 2014 Apr 08; 27(2):181-6. PubMed ID: 24515315
    [Abstract] [Full Text] [Related]

  • 6. Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.
    Kocyigit I, Yilmaz MI, Orscelik O, Sipahioglu MH, Unal A, Eroglu E, Kalay N, Tokgoz B, Axelsson J, Oymak O.
    Nephron Clin Pract; 2013 Apr 08; 123(3-4):157-64. PubMed ID: 23887359
    [Abstract] [Full Text] [Related]

  • 7. Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.
    Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V.
    Nephrol Dial Transplant; 2011 Aug 08; 26(8):2515-21. PubMed ID: 21292815
    [Abstract] [Full Text] [Related]

  • 8. Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: influence of blood pressure and humoral and neurohormonal factors.
    Martinez-Vea A, Valero FA, Bardaji A, Gutierrez C, Broch M, Garcia C, Richart C, Oliver JA.
    Am J Nephrol; 2000 Aug 08; 20(3):193-200. PubMed ID: 10878400
    [Abstract] [Full Text] [Related]

  • 9. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M, Inci A.
    Int Urol Nephrol; 2018 Jul 08; 50(7):1293-1300. PubMed ID: 29654395
    [Abstract] [Full Text] [Related]

  • 10. Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.
    Lai S, Petramala L, Mastroluca D, Petraglia E, Di Gaeta A, Indino E, Panebianco V, Ciccariello M, Shahabadi HH, Galani A, Letizia C, D'Angelo AR.
    Medicine (Baltimore); 2016 Jul 08; 95(29):e4175. PubMed ID: 27442639
    [Abstract] [Full Text] [Related]

  • 11. Endothelial dysfunction and oxidative stress in polycystic kidney disease.
    Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW.
    Am J Physiol Renal Physiol; 2014 Dec 01; 307(11):F1198-206. PubMed ID: 25234311
    [Abstract] [Full Text] [Related]

  • 12. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K, Mochizuki T, Shimada Y, Nishio S, Kataoka H, Mitobe M, Tsuchiya K, Hanaoka K, Ubara Y, Suwabe T, Sekine A, Nutahara K, Tsuruya K, Ishimura E, Nakatani S, Sofue T, Tanaka S, Narita I, Maruyama S, Horie S, Muto S.
    Clin Exp Nephrol; 2021 Sep 01; 25(9):970-980. PubMed ID: 33928479
    [Abstract] [Full Text] [Related]

  • 13. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
    Kidney Int; 2003 Sep 01; 64(3):1035-45. PubMed ID: 12911554
    [Abstract] [Full Text] [Related]

  • 14. A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease.
    Kocyigit I, Yilmaz MI, Unal A, Ozturk F, Eroglu E, Yazici C, Orscelik O, Sipahioglu MH, Tokgoz B, Oymak O.
    Am J Nephrol; 2013 Sep 01; 38(3):218-25. PubMed ID: 23988725
    [Abstract] [Full Text] [Related]

  • 15. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease.
    Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M.
    Clin J Am Soc Nephrol; 2011 Jan 01; 6(1):7-13. PubMed ID: 20829421
    [Abstract] [Full Text] [Related]

  • 16. Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients.
    Chen H, Watnick T, Hong SN, Daly B, Li Y, Seliger SL.
    BMC Nephrol; 2019 Oct 25; 20(1):386. PubMed ID: 31653199
    [Abstract] [Full Text] [Related]

  • 17. Screening of QTc interval and global autonomic activity in autosomal dominant polycystic kidney disease and atherosclerotic renal artery stenosis hypertensive patients.
    Lai S, Perrotta AM, Bagordo D, Mazzaferro S, Menè P, Gigante A, Tinti F, Galani A, Cianci R.
    Eur Rev Med Pharmacol Sci; 2021 Oct 25; 25(20):6333-6338. PubMed ID: 34730214
    [Abstract] [Full Text] [Related]

  • 18. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC, Kang AY, Jang JY, Kim H, Han M, Oh KH, Kim SH, Noh JW, Cheong HI, Hwang YH, Ahn C.
    BMC Nephrol; 2015 Jun 20; 16():86. PubMed ID: 26092580
    [Abstract] [Full Text] [Related]

  • 19. The Effect of Smoking on Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease Patients with Preserved Renal Function.
    Gul CB, Yildiz A, Sag S, Oruc A, Ersoy A, Gullulu S.
    Ren Fail; 2021 Dec 20; 43(1):1124-1129. PubMed ID: 34256663
    [Abstract] [Full Text] [Related]

  • 20. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.
    Nowak KL, Gitomer B, Farmer-Bailey H, Wang W, Malaczewski M, Klawitter J, You Z, George D, Patel N, Jovanovich A, Chonchol M.
    Am J Kidney Dis; 2019 Aug 20; 74(2):213-223. PubMed ID: 30803706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.